Jonathan F. Smith

VLP Therapeutics, Inc.

SCHOLARLY PAPERS

1

DOWNLOADS

41

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Immunogenicity of SARS-CoV-2 Self-Amplifying RNA Vaccine Expressing Anchored RBD: A Randomised, Observer-Blind, Phase 1 Study

Number of pages: 139 Posted: 24 Jan 2023
VLP Therapeutics Japan, LLC, VLP Therapeutics Japan, LLC, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, National Hospital Organization (NHO), Nagoya Medical Center, Clinical Research Center, Hokkaido University - Department of Microbiology and Immunology, VLP Therapeutics Japan, LLC, VLP Therapeutics Japan, LLC, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, Hokkaido University - Department of Microbiology and Immunology, VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics, Inc., VLP Therapeutics Japan, LLC, Kitasato University - Department of Research, Hokkaido University - Department of Microbiology and Immunology, National Hospital Organization (NHO), Nagoya Medical Center, Clinical Research Center, National Institutes of Biomedical Innovation, Health and Nutrition - Laboratory of Immunosenescence, VLP Therapeutics, Inc. and VLP Therapeutics Japan, LLC
Downloads 41 (926,710)

Abstract:

Loading...

SARS-CoV-2, self-amplifying RNA vaccine, phase 1 study